

# Bausch Health Partners with YUN to Bring Pioneering Microbiome Skincare to Poland (English)

June 23, 2025

*This strategic partnership introduces new probiotherapy solutions for managing acne-prone skin to the Polish market, with plans for future expansion.*

LAVAL, QC, June 23, 2025 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, announced today it has entered a strategic partnership with YUN NV, an innovative leader in microbiome skincare solutions. This collaboration is set to transform the skincare landscape, starting with the launch of YUN's probiotic-based products for acne-prone skin to the Polish market later this year.

YUN, known for its pioneering probiotherapeutic skincare products, and Bausch Health, a leader in the market, are combining their strengths to bring microbiome skincare solutions to new patients. The first phase of the partnership will introduce YUN's probiotic-based acne-prone skincare range to Poland later this year. These microbiome skincare solutions use live probiotics to help restore the skin's natural microbiome balance, offering a modern, science-driven approach to managing acne-prone skin. This partnership marks a significant step in expanding Bausch Health's portfolio into the emerging space of probiotherapy, a microbiome skincare approach.

"At Bausch Health, we constantly seek innovative solutions that enrich people's lives. Partnering with YUN is an exciting step forward in delivering cutting-edge microbiome technologies for acne-prone skincare in Poland, with plans to expand into other countries," said **Cees Heiman, Senior Vice President, Europe and Canada, Bausch Health**

"We're honored to partner with Bausch Health, whose strong market presence and commitment to patient well-being align with our mission to empower people and restore balance by supporting the microbiome and offering natural, effective solutions that go beyond symptoms," said **Tom Verlinden, Chief Executive Officer and Founder, YUN NV**. "This partnership validates our scientific and therapeutic vision, sharing a joint ambition to unlock the full potential of microbiome in skincare."

Both companies share a commitment to enhancing health through innovative, science-backed solutions. By joining forces, they aim to improve skin health through the science of the microbiome.

## About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit [www.bauschhealth.com](http://www.bauschhealth.com)

and connect with us on  
[LinkedIn](#)

## About Yun NV

YUN is a Belgian biotech company redefining everyday care through microbiome science. Founded in 2016, YUN developed the patented YUN Probiotherapy™ platform, featuring live probiotics and microbiome-friendly formulations designed to respect and support the skin's natural balance. With innovations across dermatological, oral, baby, intimate, and ear care, YUN delivers science- and quality-driven, nature-powered solutions for health-conscious patients and consumers, today and for generations to come. For more information about YUN, visit

[www.yun-probiotherapy.com](http://www.yun-probiotherapy.com)

and connect with us on  
[LinkedIn](#)

## Forward-looking Statements

This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

### Investor Contact:

Garen Sarafian  
[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

+1 (877) 281-6642 (toll-free)

### Media Contact:

Katie Savastano  
[corporate.communications@bauschhealth.com](mailto:corporate.communications@bauschhealth.com)

+1 (908) 569-3692

### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)  
877-281-6642  
514-856-3855 (Canada)



[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

Use of this site signifies your agreement to  
the Legal Notice and Privacy Policy.

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**